(CercleFinance.com) – Sanofi and Innate Pharma announce the expansion of their collaboration, which grants Sanofi a license to the Natural Killer (NK) cell-engaging antibody program targeting the B7-H3 protein from the ANKET platform. ‘Innate.
The health giant also acquires an option to add up to two additional targets from the ANKET platform. Once the candidates have been selected, Sanofi will be responsible for all development, manufacturing and commercialization activities.
Innate will receive an upfront payment of €25 million and up to €1.35 billion in milestone payments, plus royalties on potential net sales. The closing of the transaction is subject to the authorization of the competition authorities.
The two companies signed a first agreement around NK cell engages in 2016 to generate and evaluate up to two bispecific candidates, currently being evaluated by Sanofi’s R&D teams and one of which is in the study phase clinical.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
